IVIG for Pediatric Drug-Resistant Epilepsy
IVIG may reduce seizure frequency in some children with drug-resistant epilepsy, especially those with generalized seizures.
IVIG showed clinically meaningful seizure reduction in a subset of children with drug-resistant epilepsy, according to a retrospective analysis from a tertiary pediatric epilepsy center.
The study included 60 children aged 2–18 years with refractory seizures who received intravenous immunoglobulin for at least 1 year. Patients with autoimmune encephalitis were excluded, allowing investigators to assess IVIG in a broader pediatric drug-resistant epilepsy population rather than in a clearly autoimmune epilepsy cohort.
Seizure Reduction Seen After Long-Term IVIG
At 1 year, 36.7% of patients achieved at least a 50% reduction in seizure frequency. Among the 22 responders, 8 achieved seizure freedom, representing 36.4% of responders.
Children in the cohort had focal seizures, generalized seizures, or both seizure types. Focal seizures were reported in 38.3% of patients, generalized seizures in 36.7%, and both seizure types in 25.0%. The clearest statistical signal emerged in patients with generalized seizures, where individual seizure reduction after IVIG reached significance.
Importantly, the findings could not be explained by changes in other antiseizure medications. This supports the possibility that IVIG may have contributed to seizure improvement in selected patients, although the retrospective design limits causal interpretation.
Immune Pathways Remain a Key Question
Inflammation and immune dysfunction have been implicated in drug-resistant epilepsy, raising interest in immunomodulatory therapies for children whose seizures remain uncontrolled despite standard antiseizure medications and, in some cases, surgical options.
The exact mechanism behind IVIG benefit in pediatric epilepsy remains unclear. The response pattern in this study suggests that seizure type may matter, with generalized seizures appearing more responsive than focal seizures. However, the authors emphasized that consensus on IVIG as adjunctive therapy for children with drug-resistant epilepsy remains limited because previous studies have reported variable outcomes.
Clinical Implications for Pediatric Epilepsy Care
These findings suggest that long-term IVIG may be a therapeutic option for carefully selected children with refractory seizures, particularly when generalized seizures are present. The results also reinforce the need to better identify which pediatric epilepsy subgroups are most likely to benefit from immune-modulating treatment.
Further prospective studies are needed to clarify treatment timing, patient selection, durability of response, and safety. For now, IVIG appears to warrant continued investigation as an adjunctive therapy in pediatric drug-resistant epilepsy.
Reference
Ebdalla A et al. Efficacy of intravenous immunoglobulin in children with drug-resistant epilepsy. Front Neurol. 2026;17:1796553.
Featured Image: gpointstudio on Adobe Stock.
